Aszites – Diagnostik, Therapie und aktuelle Herausforderungen

Aszites bezeichnet die pathologische Ansammlung von Flüssigkeit in der Peritonealhöhle, die auf unterschiedlichen Mechanismen beruhen kann. Hierzulande sind die dekompensierte Leberzirrhose, die Peritonealkarzinose und die Rechtsherzinsuffizienz die häufigsten Ursachen für Aszites. In diesem Artikel werden die wesentlichen diagnostischen und therapeutischen Prinzipien bei Aszites aus der Sicht der internistischen Hepatologie erläutert.

Schlüsselwörter

Aszites - Leberzirrhose - TIPS - Diuretika - Peritonitis

• Literatur

• 1 Gu W, Hortlik H, Erasmus H-P. et al. Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Reg Health Eur 2022; 12: 100240
• 2 D’Amico G, Morabito A, D’Amico M. et al. Clinical states of cirrhosis and competing risks. J Hepatol 2018; 68: 563-576
• 3 Arroyo V, Ginès P, Gerbes AL. et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176
• 4 Gerbes AL, Labenz J, Appenrodt B. et al. [Updated S2k-Guideline “Complications of liver cirrhosis”. German Society of Gastroenterology (DGVS)]. Z Gastroenterol 2019; 57: 611-680
• 5 O’Leary JG, Greenberg CS, Patton HM. et al. AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology 2019; 157: 34-43.e1
• 6 Denzer U, Beilenhoff U, Eickhoff A. et al. [S2k guideline: quality requirements for gastrointestinal endoscopy, AWMF registry no. 021–022]. Z Gastroenterol 2015; 53: E1-E227
• 7 Patel N, Silvey S, O’Leary JG. et al. Early paracentesis is associated with better prognosis compared to late or no-paracentesis in hospitalized veterans with cirrhosis and ascites. Liver Transpl 2023; 29: 919-927
• 8 Quickert S, Würstle S, Reuken PA. et al. Real-world effectiveness of piperacillin/tazobactam with and without linezolid for spontaneous bacterial peritonitis. Dig Dis 2022; 40: 777-786
• 9 Bruns T, Reuken PA, Stengel S. et al. The prognostic significance of bacterial DNA in patients with decompensated cirrhosis and suspected infection. Liver Int 2016; 36: 1133-1142
• 10 Mahajan M, Prasad ML, Kumar P. et al. An updated systematic review and meta-analysis for the diagnostic test accuracy of ascitic fluid adenosine deaminase in tuberculous peritonitis. Infect Chemother 2023; 55: 264-277
• 11 Morando F, Rosi S, Gola E. et al. Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study. Liver Int 2015; 35: 1508-1515
• 12 Hodge C, Badgwell BD. Palliation of malignant ascites. J Surg Oncol 2019; 120: 67-73
• 13 Bernardi M, Caraceni P, Navickis RJ. et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012; 55: 1172-1181
• 14 Bureau C, Thabut D, Oberti F. et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 2017; 152: 157-163
• 15 Larrue H, D’Amico G, Olivas P. et al. TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis. J Hepatol 2023; 79: 692-703
• 16 Queck A, Schwierz L, Gu W. et al. Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS. Hepatology 2023; 77: 466-475
• 17 Kabelitz MA, Hartl L, Schaub G. et al. Identification of optimal portal pressure decrease to control ascites while minimizing hepatic encephalopathy after TIPS: A multicenter study. Hepatology 2025;
• 18 Bureau C, Thabut D, Jezequel C. et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial. Ann Intern Med 2021; 174: 633-640
• 19 Bettinger D, Sturm L, Pfaff L. et al. Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. J Hepatol 2021; 74: 1362-1372
• 20 Billey C, Billet S, Robic MA. et al. A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: The Toulouse Algorithm. Hepatology 2019; 70: 1928-1941
• 21 Terbah R, Testro AG, Hoermann R. et al. Continuous home terlipressin infusion increases handgrip strength and reduces ascites – A prospective randomized crossover study. Hepatology 2024; 80: 605-620
• 22 Fortea JI, Alvarado-Tapias E, Simbrunner B. et al. Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis. J Hepatol 2024;
• 23 Cao Z, Wong F, Choudhury AK. et al. Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium. Lancet Gastroenterol Hepatol 2024; 9: 997-1009
• 24 Silvey S, Patel NR, Tsai SY. et al. Higher rate of spontaneous bacterial peritonitis recurrence with secondary spontaneous bacterial peritonitis prophylaxis compared with no prophylaxis in 2 national cirrhosis cohorts. Am J Gastroenterol 2024;